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The expression of hypoxia-regulated genes promotes an aggressive tumour phenotype and is associated with an adverse cancer
treatment outcome. Thymidine phosphorylase (TP) levels increase under hypoxia, but the protein has not been studied in association
with hypoxia in human tumours. An investigation was made, therefore, of the relationship of tumour TP with hypoxia, the expression
of other hypoxia-associated markers and clinical outcome. This retrospective study was carried out in patients with locally advanced
cervical carcinoma who underwent radiotherapy. Protein expression was evaluated with immunohistochemistry. Hypoxia was
measured using microelectrodes and the level of pimonidazole binding. There was no relationship of TP expression with tumour pO2
(r¼ 0.091, P¼0.59, n¼87) or pimonidazole binding (r¼0.13, P¼0.45, n¼38). There was no relationship between TP and HIF-
1a, but there was a weak borderline significant relationship with HIF-2a expression. There were weak but significant correlations of
TP with the expression of VEGF, CA IX and Glut-1. In 119 patients, the presence of TP expression predicted for disease-specific
(P¼0.032) and metastasis-free (P¼0.050) survival. The results suggest that TP is not a surrogate marker of hypoxia, but is linked to
the expression of hypoxia-associated genes and has weak prognostic power.
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Thymidine phosphorylase (TP), previously called PD-ECGF, is a
110kDa protein homodimer which was originally isolated from
platelets showing endothelial mitogenic activity (Miyazono et al,
1987). It was subsequently identified in other tissues including
placenta, macrophages, lung, liver, spleen and peripheral lympho-
cytes (Yoshimura et al, 1990). Levels of the protein are elevated
in solid tumours (Yoshimura et al, 1990; Takebayashi et al, 1996,
1999), rheumatoid arthritis synovium (Asai et al, 1993) and
psoriatic lesions (Creamer et al, 1997).
Little is known about the regulation of TP expression, although
certain cytokines are implicated in increasing its activity, including
interleukin-1, tumour necrosis factor-a, fibroblast growth factor-b
and interferon-a (Tevaearai et al, 1992; Eda et al, 1993; de Bruin
et al, 2004). In vitro studies have shown that TP expression is also
induced by hypoxia. Griffiths et al (1997)found TP expression in
MDA 231 cells increased six-fold following 16h growth in 0.3%
oxygen). More recently, Abbas et al (2004) showed TP expression
increased two-fold under hypoxia in human endometrial stromal
cells. Cobalt stimulation increases TP levels, suggesting that its
expression might be regulated by hypoxia-enhancer elements, that
is, hypoxia-inducible factor (HIF) (Griffiths et al, 1997). Indeed,
Sivridis et al (2002b) showed that HIF-2a overexpression was
linked to TP expression in human endometrial adenocarcinomas.
Interestingly, in the TP-overexpressing cell line RT112-TP, TP
augmented the hypoxic induction of HIF-1a (Brown et al, 2005).
Thymidine phosphorylase has angiogenic properties (Moghaddam
et al, 1995) which are dependent on its enzymatic activity (Miyazono
et al, 1987; Miyadera et al, 1995). A relationship between TP
expression and microvessel density, a histological measure of
angiogenesis, has been reported in several solid tumours such as
breast (Toi et al, 1995a), ovarian (Reynolds et al, 1994) renal
(Imazano et al, 1997), and gastric (Takebayashi et al, 1996). In
experimental models, TP overexpression increased tumour cell
invasion (Ueda et al, 2001) and tumorigenicity (Griffiths and
Stratford 1998; Brown et al, 2005). In man, high tumour expression
of TP generally correlates with a poor prognosis in various
solid malignancies (Takebayashi et al, 1996; Ikeda et al, 1999)
including cervix cancer (Fujimoto et al, 1999; Hata et al, 1999;
Ueda et al, 1999). However, this finding is not universal, as one
study in cervix cancer showed that high tumour TP positivity was
associated with a good prognosis (Oka et al, 2003). Of interest,
high stromal TP expression correlated with a favourable prognosis
in patients with colorectal carcinoma not receiving 5-FU based
chemotherapy, which led the authors to suggest that TP produced
by tumour cells and stromal macrophages may exert different
roles (Yasuno et al, 2005).
The relationship between TP and VEGF is also of interest. There
is evidence that VEGF may act downstream of TP (Brown et al,
2000), and that hypoxia augments the effect of TP on VEGF Received 16 August 2005; accepted 27 October 2005; published online
29 November 2005
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s(Brown et al, 2005). The two proteins coexpress in breast
carcinomas (Toi et al, 1995b) and this coexpression was the most
potent angiogenic phenotype in endometrial carcinoma (Sivridis
et al, 2002a). In contrast, an inverse relationship between TP and
VEGF expression was found in cervical carcinomas (Tokumo et al,
1998) and their angiogenic activity appears highest when expressed
relatively alone in human colon cancers (Takahashi et al, 1996).
In view of the uncertainty over the role of TP, the aims of this
study were to examine the relationship of tumour TP expression
with hypoxia, the expression of hypoxia-associated proteins and
prognosis in patients with carcinoma of the cervix.
MATERIALS AND METHODS
Patients
Two series of patients were studied. Local ethical approval was
obtained and full prior written consent was gained from all the
patients. The first series of patients comprised 119 patients with
locally advanced carcinoma of the uterine cervix treated with
radical radiotherapy at the Christie Hospital NHS Trust between
1987 and 1993. Median follow-up was 60 months (range 27–115
months). Random cervical punch biopsies were taken prior to
radical radiotherapy. Treatment was given according to standard
techniques and dosages of the Manchester School (West et al,
1993). On completion of treatment they were reviewed following a
standard protocol (a minimum of three monthly for the first year,
four monthly for the second and third years, and six monthly in
the fourth and fifth years). The sites of any disease relapse were
identified clinically, radiologically, and histologically where
appropriate. The recurrences were then classified as being either
local (i.e. within the radiotherapy field) or metastatic.
The second series comprised a more recently treated group of 87
patients with locally advanced carcinoma of the cervix seen
between May 1996 and December 1999. Tumour oxygenation data
were obtained using an Eppendorf pO2 histograph as described
elsewhere (Cooper et al, 1999).
Pimonidazole binding
The method used for administration of pimonidazole to patients
(Hypoxyprobe-1; NPI Inc. Belmont, MA, USA), taking tumour
biopsies and staining have been described elsewhere (Nordsmark
et al, 2001). Patients were biopsied 12–20h after receiving
pimonidazole. A semiquantitative scoring system was used to
quantify pimonidazole binding as described elsewhere (Hutchison
et al, 2004).
TP expression
All staining was carried out on pretreatment biopsies. Immuno-
histochemical detection of TP was carried out using an immuno-
peroxidase method, as described elsewhere (Shimaoka et al, 2000).
Formalin-fixed samples were embedded in paraffin and cut into
4mm thick sections. These were then deparaffinized with xylene,
dehydrated using 100% ethanol, and washed with methanol.
Endogenous peroxidase was blocked by immersion in 0.3% H2O2
in methanol for 30min at room temperature (RT). The blocked
sections were then washed in methanol, running water and three
5min washes in TBS (pH 7.6). Slides were dried and 10% normal
rabbit serum (DAKO XO902) was applied for 10min at RT. The
sections were incubated overnight at 4
oC with a 1:30 dilution of
primary mouse monoclonal antibody (gift from Adrian Harris).
After washing, the slides were incubated for 30min at RT with
1:400 rabbit anti-mouse biotinylated secondary antibody (DAKO
EO413). The sections were then washed and incubated for 30min
at RT with streptavidin-biotin complex/horseradish peroxidase
(sABC/HRP) in TBS. Following a further wash, the slides were
incubated for 5min with 0.5mgml
 1 diaminobenzidine (DAB)
in 0.03% H2O2. The sections were washed in distilled water
and counterstained with haematoxylin before dehydrating and
mounting.
The extent and distribution of TP staining was evaluated under
low magnification, without the observer’s knowledge of outcome
data or oxygen measurements. The level of expression in the
tumour cells was evaluated using a semiquantitative scoring
system: 0 for absence of immunostaining, 1 for light staining, 2 for
moderate staining, and 3 for heavy staining. Any staining of the
tumour stroma was ignored in this assessment. All scoring was
performed in a double-blind manner by two independent
investigators.
MVD, VEGF, HIF, CA IX, Glut-1
The staining and scoring methods for MVD (Cooper et al, 1998),
VEGF (Loncaster et al, 2000), HIF-1a (Hutchison et al, 2004), HIF-
2a (Beasley et al, 2002), CA IX (Loncaster et al, 2001) and Glut-1
(Airley et al, 2001) have been described elsewhere Only tumour
nuclear HIF-1a was scored as described elsewhere (Aebersold et al,
2001). All scoring was performed in a double-blind manner by two
independent investigators.
Statistical analysis
Correlations between measurements were examined using Spear-
man’s rank correlation. The distribution of TP score in relation to
patient and tumour characteristics was investigated using Fisher’s
exact test. Survival was analysed using the Kaplan–Meier method
and prognostic factors were assessed using log-rank analysis.
Univariate and bivariate analyses were made of overall, metastasis-
free and recurrence-free survival. Patients were stratified by their
TP expression score as well as other putative prognostic factors
(stage, age, differentiation). A stepwise multivariate Cox regression
analysis was performed to further test the independence of TP
from other parameters.
RESULTS
TP expression
Positive TP expression was seen in 92% (188/206) of the tumours.
The expression was generally homogeneous within epithelial cells,
and was predominantly cytoplasmic, with some nuclear staining.
There was some degree of stromal TP expression thought to be
owing to macrophage infiltration, but this was small relative to the
tumour cytoplasmic staining. Higher levels of TP expression were
seen adjacent to areas of necrosis, but no pattern in relation to
tumour vasculature was observed.
Scoring reproducibility
Intra-observer variation in scoring TP expression was tested by re-
scoring all the tumour sections. There was a significant correlation
between the two scores (r¼0.92, Po0.001). Inter-observer
variation was tested by a second observer scoring all the same
sections. Again, there was significant correlation between the
scores (r¼0.88, P¼0.001). Assessment of batch to batch variation
showed sections stained on multiple occasions scored identically.
TP expression and tumour oxygen measurements
In a series of 87 tumours, a median of four oxygen electrode tracks
(range 1–7) was made per tumour, resulting in a median of 128
oxygen measurements (range 32–192). The median pO2 level was
4mmHg (range 0–45mmHg), and the median HP5 (percentage of
values less than 5mmHg) was 52% (range 0–96%). There was no
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ments of tumour oxygenation. The correlations with median pO2
and HP5 were r¼ 0.091, P¼0.59 and r¼ 0.014, P¼0.93,
respectively. There was no correlation between TP expression and
pimonidazole staining (r¼0.13, P¼0.45, n¼38).
Relationship with angiogenesis and hypoxia-inducible
markers
There was no relationship between TP expression and MVD
(r¼ 0.15, P¼0.10, n¼120). There was a weak positive relation-
ship between TP and VEGF expression (r¼0.36, P¼0.001, n¼89).
Expressions of both proteins were independent of disease stage
and there was no significant difference between the distributions of
the scores with stage for the two proteins. There was no significant
relationship between TP and HIF-1a expression (r¼ 0.062,
P¼0.68, n¼46). There were weak but significant positive
relationships between TP expression and CA-IX (r¼0.22,
P¼0.015, n¼122) and Glut-1 (r¼0.31, P¼0.002, n¼96). HIF-
2a showed a weak borderline significant relationship with TP
expression (r¼0.34, P¼0.09, n¼26).
Correlation with outcome
Table 1 summarises the distribution of tumour TP expression in
relation to patient and tumour characteristics in 119 patients.
Using Fisher’s exact test, TP expression was independent of
tumour stage and differentiation. Higher levels of expression were
seen in tumour from younger patients.
Figure 1 illustrates the relationship between TP expression and
treatment outcome. The level of expression was a significant
prognostic factor for metastasis-free survival (P¼0.031) and a
borderline significant prognostic factor for disease-specific survi-
val (P¼0.067). There was no relationship with local control
(P¼0.23). The analyses were repeated stratifying patients by the
presence or absence of immunostaining (Figure 2). The prognostic
significance of TP expression was similar for both disease-specific
(P¼0.032) and metastasis-free (P¼0.050) survival. The sensitivity
of TP in predicting a poor outcome was 96% for both disease-
specific and metastasis-free survival. However, the respective
specificities were only 16 and 14%. The respective positive
predictive values of tumour TP positivity were 50 and 44%. Table 2
summarises the results of univariate log-rank analyses of outcome
following radiotherapy. Tumour stage was the strongest prognostic
factor, followed by TP expression. Bivariate analyses were carried
out examining the prognostic significance of TP expression after
allowing for disease stage, tumour grade and patient age (Table 3).
TP expression remained a weak predictor of disease-free and
metastasis-free survival after allowing for disease stage, patient age
and tumour grade. Adding the scores for TP and VEGF expression
did not improve the prognostic ability over VEGF expression alone
for disease-specific and metastasis-free survival (P¼0.0057 and
P¼0.0024, respectively). However, the combined score was better
at predicting local control than either VEGF or TP alone
(P¼0.029).
DISCUSSION
The immunohistochemical detection of the intensity of TP
expression has been shown to correlate with TP levels as
determined by immunoassay (Fujimoto et al, 1999). The scoring
Table 1 Distribution of patients according to TP expression
TP score
Parameter N 0 123 P
a
Stage
I 32 6 10 11 5 0.13
II 34 2 9 9 14
III 45 4 14 18 9
IV 8 0 5 1 2
Age
o52years 59 9 18 11 21 0.002
452years 60 3 20 28 9
Differentiation
Well 23 1 7 8 7 0.97
Moderate 74 8 24 24 18
Poor 16 1 6 5 4
aP¼statistical significance using Fisher’s exact test.
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Figure 1 Disease-specific survival (A), metastasis-free survival (B) and
local control (C), in relation to TP expression in 119 cervical cancer
patients who received radical radiotherapy. Patients were stratified
according to the intensity of TP expression (0¼no staining, 1¼light
staining, 2¼moderate staining and 3¼heavy staining). The numbers of
events and patients in each arm are indicated.
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was reproducible within and between scorers. The cytoplasmic
distribution of TP in our study is consistent with series in uterine
cancers (Fujimoto et al, 1999) and other malignancies (Reynolds
et al, 1994; Moghaddam et al, 1995; Toi et al, 1995a; Takebayashi
et al, 1996). However, some groups have described stromal
macrophage TP expression in colorectal cancer (Saito et al,
2000) and adenocarcinoma of the lung (Kojima et al, 2002).
This is the only study, to the authors’ knowledge, that has
examined the relationship between TP expression and measure-
ments of hypoxia in human tumours. In this study, no relationship
was demonstrated between TP expression and hypoxia. As
previously discussed, stimuli other than hypoxia are involved in
TP expression. TP is upregulated not only by cytokines (see
Introduction), but also by low pH (Griffiths et al, 1997) and the
activation of oncogenes such as c-erbB-2 and loss of Bcl-2
(Koukourakis et al, 1999). Another factor confounding the
relationship between TP and hypoxia might relate to its role in
stimulating angiogenesis. In comparison with wild-type cells,
xenografted TP-overexpressing breast cancer cells were shown
to be better oxygenated (measured using the comet assay).
The authors suggested the finding was consistent with the TP-
overexpressing tumours having an increased and functionally
more competent vasculature (Griffiths and Stratford, 1998).
Clearly, the relationships between hypoxia, angiogenesis and TP
are unlikely to be simple. How the relationships might change
during tumorigenesis, that is, from pre-malignant to early stage to
advanced disease, remains to be explored.
Although TP is upregulated under hypoxia, we found no
relationship between the expression of TP and HIF-1a in cervix
tumours. As for TP, HIF-1a protein levels can be raised in tumours
due to stimuli other than hypoxia: activation of oncogenes HER2
(Laughner et al, 2001), v-src (Jiang et al, 1997) and H-ras (Chen
et al, 2001); loss of tumour suppressor gene function such as PTEN
(Zundel et al, 2000) and signalling abnormalities such as MAPK
(Richard et al, 1999). The relationship between TP and HIF has not
been studied widely. While we found no relationship between TP
and HIF-1a expression there was a borderline correlation with
HIF-2a. This observation is consistent with a finding in human
endometrial cancers of an association between tumour expression
of TP and HIF-2a but not HIF-1a (Sivridis et al, 2002b). Recent
evidence showed that whereas some genes are upregulated by HIF-
1a and HIF-2a, others are preferentially activated by one or the
other factor (Wang et al, 2005). It might be, therefore, that TP is
preferentially induced by HIF-2a. Of interest is the observation
that TP increased the hypoxic expression of HIF-1a in an orthoptic
xenograft model of bladder cancer (Brown et al, 2005). This
finding suggests that TP can be added to the long list of factors that
promote HIF activation.
Consistent with the suggestion that TP promotes HIF-a
expression, we found weak relationships between tumour TP
expression and the expression of proteins upregulated by HIF
(VEGF, CAIX and Glut-1). These results are also consistent with
published evidence showing either a correlation or coexpression of
TP with VEGF (Fujimoto et al, 1998; O’Byrne et al, 2000; van Triest
et al, 2000) and CA-IX (Giatromanolaki et al, 2001). Studies have
also shown that TP may stimulate VEGF expression. Increasing TP
enzymatic activity induces oxidative stress which has been shown
to upregulate various cytokines including VEGF (Brown et al,
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Figure 2 Disease-specific survival (A), metastasis-free survival (B) and
local control (C) in relation to the presence or absence of TP expression in
119 cervical cancer patients who received radical radiotherapy. The
numbers of events and patients in each arm are indicated.
Table 2 Univariate log-rank analysis of putative prognostic factors for
outcome following radiotherapy for carcinoma of the cervix
Parameter n
Disease-specific
survival
Metastasis-
free survival
Local
control
Stage 119 o0.001 0.005 0.11
Age 119 0.65 0.12 0.043
Differentiation 113 0.81 0.69 0.25
TP expression
a 119 0.067 0.031 0.23
aAnalysed using univariate Cox test for trend The P-value for each factor is given.
Table 3 Bivariate stratified log-rank analyses showing the significance of
the level of TP expression as a prognostic factor after allowing for the listed
parameters
Parameter n
Disease-specific
survival
Metastasis-
free survival
Local
control
Stage 119 0.091 0.049 0.21
Age 119 0.19 0.053 0.25
Differentiation 113 0.21 0.078 0.30
The P-value for each factor is given.
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expression under hypoxic conditions in vivo (Brown et al, 2005).
Our data support this relationship. TP and its enzymatic products
have been shown to be angiogenic in various models (Moghaddam
et al, 1995; Jones et al, 2002). These effects may be synergistic with
or mediated by VEGF.
This study found TP expression to be a weak prognostic
indicator in locally advanced carcinoma of the cervix. As we
showed previously for VEGF (Loncaster et al, 2000), TP
significantly predicted for metastasis-free survival but not local
control. This is consistent with its role as a promoter of tumour
angiogenesis rather than a role in hypoxia-associated radio-
resistance.
The exact role of TP in tumorigenesis and angiogenesis remains
unclear. Studies have shown that the use of TP inhibitors in TP-
overexpressing xenografted cell lines reduced angiogenesis and
increased apoptosis (Matsushita et al, 1999). These results have not
yet been developed into clinical trials. Nevertheless, owing to
tumour-specific activating and deactivating mutations, the efficacy
of TP inhibitors might vary not only between individual tumours
but also between different types of tumours. Emphasis should be
placed on elucidating the exact relationship of TP with other
angiogenic factors, HIF, signalling abnormalities, oncogene
activation and loss of tumour suppressor gene function. Such
information should prove useful for the successful introduction of
TP inhibition strategies into clinical practice.
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